120 related articles for article (PubMed ID: 36582107)
1. DOSE RELATIONSHIP DURING RADIOABLATION OF THYROID RESIDUAL IN PATIENTS WITH THYROID DIFFERENTIATED CANCER.
Dzhuzha DO
Probl Radiac Med Radiobiol; 2022 Dec; 27():431-439. PubMed ID: 36582107
[TBL] [Abstract][Full Text] [Related]
2. "High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma.
Menzel C; Grünwald F; Schomburg A; Palmedo H; Bender H; Späth G; Biersack HJ
J Nucl Med; 1996 Sep; 37(9):1496-503. PubMed ID: 8790201
[TBL] [Abstract][Full Text] [Related]
3. Low-dose radioiodine therapy for patients with intermediate- to high-risk differentiated thyroid cancer.
Abe K; Ishizaki U; Ono T; Horiuchi K; Kanaya K; Sakai S; Okamoto T
Ann Nucl Med; 2020 Feb; 34(2):144-151. PubMed ID: 31834567
[TBL] [Abstract][Full Text] [Related]
4. Negative remnant
Lan W; Gege Z; Ningning L; Qiang W; Lin B; Qingjie M; Bin J
Ann Nucl Med; 2019 Feb; 33(2):112-118. PubMed ID: 30374858
[TBL] [Abstract][Full Text] [Related]
5. Predictive Value of a Thyroid-Absorbed Dose with a Shorter Effective Half-Life on Efficacy in Graves Disease Patients Receiving Iodine-131 Therapy.
Yu F; Zhang R; Zhang G; Meng Z; Liu X; He Y; Tan J; Wang R
Med Sci Monit; 2021 Jan; 27():e928796. PubMed ID: 33497370
[TBL] [Abstract][Full Text] [Related]
6. Fractionated dosage of radioiodine for the ablation of low-risk differentiated thyroid cancer has no impact on survival.
Woliński K; Czepczyński R; Stangierski A; Trojanowski M; Rewaj-Łosyk M; Ziemnicka K; Bączyk M; Dyzmann-Sroka A; Ruchała M
Endokrynol Pol; 2018; 69(3):230-234. PubMed ID: 29504625
[TBL] [Abstract][Full Text] [Related]
7. Radiation dose assessment in radioiodine therapy. Dose-response relationships in differentiated thyroid carcinoma using quantitative scanning and PET.
O'Connell ME; Flower MA; Hinton PJ; Harmer CL; McCready VR
Radiother Oncol; 1993 Jul; 28(1):16-26. PubMed ID: 8234866
[TBL] [Abstract][Full Text] [Related]
8. Five months' follow-up of patients with and without iodine-positive lymph node metastases of thyroid carcinoma as disclosed by (131)I-SPECT/CT at the first radioablation.
Schmidt D; Linke R; Uder M; Kuwert T
Eur J Nucl Med Mol Imaging; 2010 Apr; 37(4):699-705. PubMed ID: 19936746
[TBL] [Abstract][Full Text] [Related]
9. Radioiodine ablation in thyroid cancer patients: renal function and external radiation dose rate at discharge according to patient preparation.
Han YH; Jeong HJ; Sohn MH; Lee SY; Lim ST
Q J Nucl Med Mol Imaging; 2020 Mar; 64(1):124-130. PubMed ID: 29521481
[TBL] [Abstract][Full Text] [Related]
10. [Results of radioiodine treatment of patients with immunogenic and non-immunogenic hyperthyroidism using different focal doses].
Moser E; Pickardt CR; Mann K; Engelhardt D; Kirsch CM; Knesewitsch P; Tatsch K; Kreisig T; Kurz C; Saller B
Nuklearmedizin; 1988 Jun; 27(3):98-104. PubMed ID: 3405782
[TBL] [Abstract][Full Text] [Related]
11. The clinical significance of remnant thyroid tissue in thyroidectomized differentiated thyroid cancer patients on
Wang F; Nie H; Li W; Zhang R; Li W
BMC Med Imaging; 2021 May; 21(1):78. PubMed ID: 33964885
[TBL] [Abstract][Full Text] [Related]
12. Radioiodine lobar ablation as an alternative to completion thyroidectomy in patients with differentiated thyroid cancer.
Bal CS; Kumar A; Pant GS
Nucl Med Commun; 2003 Feb; 24(2):203-8. PubMed ID: 12548045
[TBL] [Abstract][Full Text] [Related]
13. Radioiodine therapy reduces the frequency of circulating tumour cells in patients with differentiated thyroid cancer.
Schmidt M; Antke C; Mattes-György K; Hautzel H; Allelein S; Haase M; Dringenberg T; Schott M; Ehlers M
Clin Endocrinol (Oxf); 2021 Jun; 94(6):1004-1011. PubMed ID: 33484159
[TBL] [Abstract][Full Text] [Related]
14. Indirect assessment of the maximum empirical activity (250 mCi) with respect to dosimetry concepts in radioiodine therapy of metastatic differentiated thyroid cancer.
Abuqbeitah M; Demir M; Kabasakal L; Çavdar İ; Uslu-Beşli L; Yeyin N; Razavikhosroshahi S; Sönmezoğlu K
Nucl Med Commun; 2018 Nov; 39(11):969-975. PubMed ID: 30180046
[TBL] [Abstract][Full Text] [Related]
15. Radioiodine therapy for well-differentiated thyroid cancer: a quantitative dosimetric evaluation for remnant thyroid ablation after surgery.
Samuel AM; Rajashekharrao B
J Nucl Med; 1994 Dec; 35(12):1944-50. PubMed ID: 7989975
[TBL] [Abstract][Full Text] [Related]
16. Variations in Radioiodine Therapy in Europe: Decision-Making after Total Thyroidectomy.
Forrer F; Fischer GF; Maas O; Giovanella L; Hoffmann M; Iakovou I; Luster M; Mihailovic J; Petranovic Ovčariček P; Vrachimis A; Zerdoud S; Putora PM
Oncology; 2022; 100(2):74-81. PubMed ID: 34788758
[TBL] [Abstract][Full Text] [Related]
17. Acute toxicity of adjuvant radiotherapy in locally advanced differentiated thyroid carcinoma. First results of the multicenter study differentiated thyroid carcinoma (MSDS).
Schuck A; Biermann M; Pixberg MK; Müller SB; Heinecke A; Schober O; Willich N
Strahlenther Onkol; 2003 Dec; 179(12):832-9. PubMed ID: 14652672
[TBL] [Abstract][Full Text] [Related]
18. Response to Therapy Assessment in Intermediate-Risk Thyroid Cancer Patients: Is Thyroglobulin Stimulation Required?
Moreno I; Hirsch D; Duskin-Bitan H; Dicker-Cohen T; Shimon I; Robenshtok E
Thyroid; 2020 Jun; 30(6):863-870. PubMed ID: 31928205
[No Abstract] [Full Text] [Related]
19. Outcome of radioiodine therapy in thyroid cancer patients with recent contrasted computed tomography.
Rodriguez JD; Kirk D; Benefield T; Maygarden SJ; Pou K; Kim LT; Hackman TG; Khandani AH
Nucl Med Commun; 2020 Mar; 41(3):228-234. PubMed ID: 31895755
[TBL] [Abstract][Full Text] [Related]
20. Rate of elimination of radioiodine-avid lymph node metastases of differentiated thyroid carcinoma by postsurgical radioiodine ablation. A bicentric study.
Ilhan H; Mustafa M; Bartenstein P; Kuwert T; Schmidt D
Nuklearmedizin; 2016 Dec; 55(6):221-227. PubMed ID: 27588323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
